| scholarly article | Q13442814 |
| P50 | author | Tom Bourne | Q45956465 |
| P2093 | author name string | Adrian Moore | |
| Bruce Carrington | |||
| Terry Baker | |||
| Chris Meier | |||
| Alistair Henry | |||
| Alastair Lawson | |||
| Andrew Popplewell | |||
| Diane Marshall | |||
| Ralph Adams | |||
| Stevan Shaw | |||
| Steve Rapecki | |||
| Helen Neale | |||
| Rich Gelinas | |||
| P2860 | cites work | Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis | Q22251072 |
| Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex | Q24306425 | ||
| Rationale for interleukin-6 blockade in systemic lupus erythematosus | Q24564990 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| MolProbity: all-atom structure validation for macromolecular crystallography | Q24649111 | ||
| Inflammatory cytokines in systemic lupus erythematosus | Q26823647 | ||
| Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling | Q27002391 | ||
| Structural changes in a cryo-cooled protein crystal owing to radiation damage | Q27621730 | ||
| Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 | ||
| Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition | Q27666518 | ||
| Conservation of Functional Sites on Interleukin-6 and Implications for Evolution of Signaling Complex Assembly and Therapeutic Intervention | Q27673832 | ||
| Bound water molecules and conformational stabilization help mediate an antigen-antibody association | Q27731557 | ||
| Inference of macromolecular assemblies from crystalline state | Q27860457 | ||
| Coot: model-building tools for molecular graphics | Q27860505 | ||
| Integration of macromolecular diffraction data | Q27860752 | ||
| Phasercrystallographic software | Q27860930 | ||
| Refinement of macromolecular structures by the maximum-likelihood method | Q27861011 | ||
| Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study | Q33527462 | ||
| Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial | Q34092311 | ||
| Target discovery | Q34267418 | ||
| Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6 | Q34407431 | ||
| Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains | Q34469106 | ||
| The paradigm of IL-6: from basic science to medicine | Q34731226 | ||
| Activation of the STAT1 pathway in rheumatoid arthritis | Q35553848 | ||
| Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions | Q35724900 | ||
| Identifying bottlenecks in transient and stable production of recombinant monoclonal-antibody sequence variants in Chinese hamster ovary cells | Q36089255 | ||
| A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities | Q37444686 | ||
| Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor | Q37462533 | ||
| A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato | Q37465508 | ||
| Therapeutic antibodies: successes, limitations and hopes for the future | Q37491236 | ||
| Interleukin-6: From identification of the cytokine to development of targeted treatments | Q37792471 | ||
| The pro- and anti-inflammatory properties of the cytokine interleukin-6. | Q37836084 | ||
| IL-6/IL-6 receptor system and its role in physiological and pathological conditions | Q37949664 | ||
| Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases. | Q38029235 | ||
| IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. | Q38058509 | ||
| 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling | Q42611750 | ||
| Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer | Q42626935 | ||
| A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro | Q44572783 | ||
| IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. | Q46372900 | ||
| IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. | Q51773865 | ||
| Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. | Q54768818 | ||
| Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo | Q57079498 | ||
| Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis | Q57128078 | ||
| The use of ELISA for detection of the antibody-induced conformational change in a viral protein and its intermolecular spread | Q67294732 | ||
| Engineering Antibodies for Therapy | Q67470988 | ||
| Evidence for continuous stimulation of interleukin-6 production in Crohn's disease | Q67531210 | ||
| Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production | Q73271380 | ||
| A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate | Q83431012 | ||
| A systematic comparison of free and bound antibodies reveals binding-related conformational changes | Q87444426 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 774-782 | |
| P577 | publication date | 2014-04-02 | |
| P1433 | published in | Monoclonal Antibodies | Q6714645 |
| P1476 | title | Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling | |
| P478 | volume | 6 |
| Q38931171 | An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo |
| Q26774874 | Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review |
| Q41050325 | Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model |
| Q42078390 | Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling |
| Q38336406 | From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis |
| Q57031835 | Humanization of Antibodies using a Statistical Inference Approach |
| Q38433045 | IL-6 as a keystone cytokine in health and disease |
| Q88562718 | Interleukin-6: designing specific therapeutics for a complex cytokine |
| Q36283919 | Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex |
| Q93358519 | Post-stroke inflammation-target or tool for therapy? |
| Q26769917 | Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer |
| Q38382090 | Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases |
| Q54110138 | Regulatory effect of anti-gp130 functional mAb on IL-6 mediated RANKL and Wnt5a expression through JAK-STAT3 signaling pathway in FLS. |
| Q26743557 | Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6 |
| Q42547820 | Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies. |
| Q91598124 | Targeting senescent cells: approaches, opportunities, challenges |
| Q47109861 | The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. |
Search more.